The global biological implants market accounted for USD 8.51 billion in 2023 and is expected to reach at USD 18.35 billion by 2034 with a CAGR of 7.23% during the forecast period 2024-2034. The prevalence of chronic diseases, technological advancements, an aging population, and an increasing demand for minimally invasive surgeries will all fuel market expansion.
Advances in biomaterials research, tissue engineering, and 3D printing are resulting in the creation of novel and improved biological implants. These implants provide greater functionality, biocompatibility, and lifespan, making them more appealing to both patients and surgeons. For instance, DePuy Synthes expanded their range of minimally invasive spine surgery solutions in February 2023 with the debut of the CONCORDE Clear MIS Discectomy Device.
By product, the xenografts segment accounted for the highest revenue-grossing segment in the global biological implants market in 2023 owing to the increasing demand for xenografts due to their availability, compatibility, and efficacy in various medical applications, alongside advancements in xenotransplantation techniques and rising prevalence of organ failure. For instance, in December 2023, Stryker announced the acquisition of OrthoSensor, Inc., an organization specializing in sensor technologies for orthopedic procedures, which will strengthen Stryker's digital surgery platform. Additionally, the allografts segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing acceptance of allografts due to their reduced risk of immune rejection, wider availability, and advancements in tissue matching techniques, coupled with rising demand for organ transplantation and orthopedic procedures.
By application, the other soft tissue implants segment accounted for the highest revenue-grossing segment in the global biological implants market in 2023 owing to the growing demand for soft tissue repair and reconstruction solutions, driven by the rising incidence of injuries, deformities, and cosmetic procedures, alongside technological advancements improving implant materials and surgical techniques. For instance, Zimmer Biomet got FDA certification for their ROSA Partial Knee System in September 2023, increasing its orthopedic robotic surgery services. Additionally, the cardiovascular implants segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of cardiovascular diseases, rising adoption of minimally invasive procedures, advancements in cardiovascular implant technologies, and expanding elderly population susceptible to heart-related conditions.
By mode of administration, the surgical segment accounted for the highest revenue-grossing segment in the global biological implants market in 2023 owing to the growing demand for surgical procedures across various medical specialties, advancements in surgical techniques and technologies, and increasing prevalence of chronic diseases requiring surgical interventions. For instance, in November 2023, Boston Scientific announced the completion of its acquisition of Devoro Medical, Inc., which expanded its line of minimally invasive venous disease treatments. Additionally, the injectable segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for minimally invasive procedures, advancements in injectable implant materials and delivery systems, and expanding applications in cosmetic, orthopedic, and regenerative medicine fields.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global biological implants market in 2023 owing to the increased adoption of advanced medical procedures, rising demand for implant-related surgeries, and expanding healthcare infrastructure in hospitals globally. For instance, in November 2023, Boston Scientific announced the completion of its acquisition of Devoro Medical, Inc., which will expand its line of minimally invasive venous disease treatments. Additionally, the ambulatory surgical center segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend towards outpatient surgeries, advancements in minimally invasive procedures, increasing patient preference for convenience and shorter recovery times and expanding availability of ambulatory surgical centers.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high healthcare expenditure, presence of advanced healthcare infrastructure, increasing prevalence of chronic diseases, robust research and development activities, and favorable reimbursement policies in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, rising healthcare expenditure, increasing prevalence of chronic diseases, growing geriatric population, and increasing adoption of advanced medical technologies in the Asia Pacific region. For instance, Integra LifeSciences announced the acquisition of Rebound Therapeutics Corporation in October 2023, broadening its neurosurgery portfolio with breakthrough technology for the treatment of neurovascular illnesses.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Advances in biomaterials research, tissue engineering, and 3D printing are resulting in the creation of novel and improved biological implants. These implants provide greater functionality, biocompatibility, and lifespan, making them more appealing to both patients and surgeons. For instance, DePuy Synthes expanded their range of minimally invasive spine surgery solutions in February 2023 with the debut of the CONCORDE Clear MIS Discectomy Device.
By product, the xenografts segment accounted for the highest revenue-grossing segment in the global biological implants market in 2023 owing to the increasing demand for xenografts due to their availability, compatibility, and efficacy in various medical applications, alongside advancements in xenotransplantation techniques and rising prevalence of organ failure. For instance, in December 2023, Stryker announced the acquisition of OrthoSensor, Inc., an organization specializing in sensor technologies for orthopedic procedures, which will strengthen Stryker's digital surgery platform. Additionally, the allografts segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing acceptance of allografts due to their reduced risk of immune rejection, wider availability, and advancements in tissue matching techniques, coupled with rising demand for organ transplantation and orthopedic procedures.
By application, the other soft tissue implants segment accounted for the highest revenue-grossing segment in the global biological implants market in 2023 owing to the growing demand for soft tissue repair and reconstruction solutions, driven by the rising incidence of injuries, deformities, and cosmetic procedures, alongside technological advancements improving implant materials and surgical techniques. For instance, Zimmer Biomet got FDA certification for their ROSA Partial Knee System in September 2023, increasing its orthopedic robotic surgery services. Additionally, the cardiovascular implants segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of cardiovascular diseases, rising adoption of minimally invasive procedures, advancements in cardiovascular implant technologies, and expanding elderly population susceptible to heart-related conditions.
By mode of administration, the surgical segment accounted for the highest revenue-grossing segment in the global biological implants market in 2023 owing to the growing demand for surgical procedures across various medical specialties, advancements in surgical techniques and technologies, and increasing prevalence of chronic diseases requiring surgical interventions. For instance, in November 2023, Boston Scientific announced the completion of its acquisition of Devoro Medical, Inc., which expanded its line of minimally invasive venous disease treatments. Additionally, the injectable segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for minimally invasive procedures, advancements in injectable implant materials and delivery systems, and expanding applications in cosmetic, orthopedic, and regenerative medicine fields.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global biological implants market in 2023 owing to the increased adoption of advanced medical procedures, rising demand for implant-related surgeries, and expanding healthcare infrastructure in hospitals globally. For instance, in November 2023, Boston Scientific announced the completion of its acquisition of Devoro Medical, Inc., which will expand its line of minimally invasive venous disease treatments. Additionally, the ambulatory surgical center segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend towards outpatient surgeries, advancements in minimally invasive procedures, increasing patient preference for convenience and shorter recovery times and expanding availability of ambulatory surgical centers.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high healthcare expenditure, presence of advanced healthcare infrastructure, increasing prevalence of chronic diseases, robust research and development activities, and favorable reimbursement policies in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, rising healthcare expenditure, increasing prevalence of chronic diseases, growing geriatric population, and increasing adoption of advanced medical technologies in the Asia Pacific region. For instance, Integra LifeSciences announced the acquisition of Rebound Therapeutics Corporation in October 2023, broadening its neurosurgery portfolio with breakthrough technology for the treatment of neurovascular illnesses.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Application, Mode of Administration, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Biological Implants Market Report 2023 - 2034
Biological Implants Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Autografts
- Allograft
- Xenografts
Biological Implants Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Cardiovascular Implants
- Orthopedic Implants
- Other Soft Tissue Implants
Biological Implants Market Analysis & Forecast by Mode of Administration 2023 - 2034 (Revenue USD Bn)
- Surgical
- Injectable
Biological Implants Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Clinics
- Ambulatory Surgical Centre
- Others
Biological Implants Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Biological Implants Market: Product Estimates & Trend Analysis
8. Biological Implants Market: Application Estimates & Trend Analysis
9. Biological Implants Market: Mode of Administration Estimates & Trend Analysis
10. Biological Implants Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Biological Implants Market
13. Europe Global Biological Implants Market
14. Asia Pacific Global Biological Implants Market
15. Latin America Global Biological Implants Market
16. MEA Global Biological Implants Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Medtronic plc
- Johnson & Johnson (DePuy Synthes)
- Stryker Corporation
- Zimmer Biomet Holdings Inc. Boston Scientific Corporation
- Smith & Nephew plc
- Abbott Laboratories
- Integra LifeSciences Holdings Corporation
- Baxter International Inc.
- Wright Medical Group N.V. (now part of Stryker Corporation)
- B. Braun Melsungen AG
- Cook Medical Inc.
- Olympus Corporation
- NuVasive Inc.
- LivaNova PLC.
